Top Markets
Coin of the day
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
Rankning i aktier #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Aktiekurs
$19.30
Senast synkroniserad: 2023-12-26
Marknadsvärde
$72.77M
Förändring (1 dag)
6.22%
Förändring (1 år)
0.00%
Land
US
Handel Aeglea BioTherapeutics, Inc. (AGLE)

Kategori

Aktiekurshistorik för Aeglea BioTherapeutics, Inc. (AGLE)
Högsta slutkurs: $17.81 den 2023-12-01

Lägsta slutkurs: $240.00 den 2016-04-01
Aktiekurshistorik för Aeglea BioTherapeutics, Inc. från 2016 till 2026
Årlig aktiekursutveckling
År Prestanda
2023 80.43%
2022 -90.79%
2021 -48.55%
2020 6.06%
2019 3.25%
2018 49.19%
2017 -3.90%
2016 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH